Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01871935
Other study ID # SuRe-002
Secondary ID
Status Recruiting
Phase N/A
First received May 30, 2013
Last updated January 30, 2014
Start date June 2013
Est. completion date June 2014

Study information

Verified date January 2014
Source University Medical Center Groningen
Contact Alain F Kalmar, MD, PhD
Email a.f.kalmar@umcg.nl
Is FDA regulated No
Health authority Netherlands: Medical Ethics Review Committee (METC)
Study type Interventional

Clinical Trial Summary

Induction of general anaesthesia with a combination of opiates and hypnotics often induces vasodilation resulting in several haemodynamic effects such as a decrease in blood pressure (MAP), heart rate (HR) and cardiac output (CO). This haemodynamic suppression may jeopardize tissue oxygenation, particularly cerebral oxygenation. Previous research of the investigators group has revealed that atropine has an exceptionally beneficial effect on the determinants of tissue oxygen delivery as well as on tissue oxygenation. The investigators have demonstrated a significant and clinically relevant increase in CO and cerebral tissue oxygenation (SctO2) for a desired increase in MAP. This is in steep contrast with the more usual clinical practice of administrating classical vasoactive medication such as phenylephrine or norepinephrine, since the two latter have an even negative effect on CO and SctO2. In previous research the investigators used standardized target controlled propofol/remifentanil infusions for induction and maintenance of anaesthesia. It is known that remifentanil has more intense haemodynamic side-effects compared to other opiates such as fentanyl, sufentanil or alfentanil. This raises the question whether the beneficial effect of atropine is restricted to propofol/remifentanil anaesthesia, or if this is equally valid during anaesthesia of propofol combined with other opiates such as sufentanil.

Patients undergoing off-pump coronary artery bypass grafting (CABG) require a long and deep general anaesthesia, which is usually performed with the combination of drugs as mentioned above. Because these patients often experience severe haemodynamic fluctuations they need to be closely monitored.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date June 2014
Est. primary completion date October 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age: 18 years and older.

- Elective CABG surgery performed off-pump.

- Written informed consent to participate in this study.

- Patient and surgical procedure appropriate for treatment with either sufentanil or remifentanil.

Exclusion Criteria:

- Refusal to participate in this study.

- Age: younger than 18 years.

- Pregnant.

- BMI > 35 kg/m2.

- Patients in which atropine is contra-indicated.

- Patients in which sufentanil or remifentanil at the proposed doses are contra-indicated.

- Urgent or emergency surgery.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Haemodynamic Fluctuations During Off-pump CABG.

Intervention

Drug:
Remifentanil
Anaesthesia with remifentanil/propofol.
Sufentanil
Anaesthesia with sufentanil/propofol

Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (1)

Lead Sponsor Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary CO During anaesthesia No
Secondary MAP During anaesthesia No
Secondary Tissue oxygen saturation During anaesthesia No
Secondary CO CO obtained by different devices/methods (i.e. the Vigileo device and TEE) During anaesthesia No